UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

01 UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

Read More Share:

Aug

17 UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

Read More Share:

May

23 UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

Read More Share:

May

23 First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

Read More Share:

May

10 Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively.

Read More Share:

May

10 UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Read More Share:

Mar

28 FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Read More Share:

Mar

26 New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Read More Share:

Mar

07 UCB Completes Acquisition of Zogenix, Inc.

Read More Share:

Feb

04 UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Read More Share:

Categories

Archives

Sep

01

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

Aug

17

UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

May

23

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

May

23

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

May

10

Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Mar

26

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Mar

07

UCB Completes Acquisition of Zogenix, Inc.

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Sep

01

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

Aug

17

UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

May

23

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

May

23

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

May

10

Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Mar

26

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Mar

07

UCB Completes Acquisition of Zogenix, Inc.

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact